Palliative care (PC) plays an established role in improving outcomes in patients with solid tumors, yet these services are underutilized in hematologic malignancies (HMs). We reviewed records of ...

Patients with hematologic malignancies are at high risk of thrombotic or hemorrhagic complications. The incidence of these events is greatly variable and is influenced by many factors, including the ...

Survivors of hematologic cancers are at high risk of developing cardiovascular disease (CVD), according to a study published online June 22 in BMC Cancer. Siqing Liu, from Hangzhou Normal University ...

Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic ...

The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the ...

Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera. There were several notable updates to have come out of ...

Sikander Ailawadhi, MD, discusses how the studies presented at ASH 2024 highlight significant unmet needs in hematologic cancer management, emphasizing the potential for these findings to influence ...

Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. We analyzed ...

Patients with hematologic disease are at an elevated risk of morbidity and mortality post-infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. It is currently unknown ...

Please provide your email address to receive an email when new articles are posted on . Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody ...